CTOR

Financial Scores

CTOR’s price-to-free cash flow ratio: A closer look at its relevance

Cameron Mitchell

Its current price is -80.61% under its 52-week high of $6.19 and 117.94% more than its 52-week low of $0.55. ...

Market Summary

Citius Oncology Inc (CTOR) presents a great opportunity, but the stock is slightly undervalued

Cameron Mitchell

While Citius Oncology Inc has underperformed by -10.07%, investors are advised to look at stock chart patterns for technical insight. ...

Analyst Snapshot

Citius Oncology Inc (CTOR) is a good investment, but the stock may be undervalued

Cameron Mitchell

While Citius Oncology Inc has underperformed by -1.72%, investors are advised to look at stock chart patterns for technical insight. ...

US Post News
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.